All In MedTech

FDA Clearance Tracker · P230036

Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Apr 26, 2024

Approved

Time to decision

178 days

Received Oct 31, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230036
Device name
Esprit™ BTK Everolimus Eluting Resorbable Scaffold System
Applicant location
Santa Clara, CA
Received
Oct 31, 2023
Decided
Apr 26, 2024
Decision
Approved
Supplements
19 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code NXW

FDA's approval statement

As written in FDA's record.

The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with Chronic Limb Threatening Ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of >= 2.5 mm and <= 4.00 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NXW (Scaffold, infrapopliteal, absorbable).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.